Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 2380

Sort by

Sort Order Select

Journal Articles

Clonal evolution of acute myeloid leukemia with FLT3 -ITD mutation under treatment with midostaurin

Blood (2021) 137 (22): 3093–3104.

https://doi.org/10.1182/blood.2020007626

Published: 2021

Includes: Supplemental data

Journal Articles

Acute myeloid leukemia with NPM1 and FLT3 ITD mimicking acute promyelocytic leukemia

Michael Pepper, Brent Tan

Blood (2020) 136 (12): 1467.

https://doi.org/10.1182/blood.2020007198

Published: 2020

Journal Articles

FLT3 inhibition upregulates HDAC8 via FOXO to inactivate p53 and promote maintenance of FLT3-ITD + acute myeloid leukemia

Blood (2020) 135 (17): 1472–1483.

https://doi.org/10.1182/blood.2019003538

Published: 2020

Includes: Supplemental data

Journal Articles

Molecular MRD status and outcome after transplantation in NPM1 -mutated AML

Blood (2020) 135 (9): 680–688.

https://doi.org/10.1182/blood.2019002959

Published: 2020

Includes: Supplemental data

Journal Articles

Impact of NPM1 / FLT3 -ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia

Blood (2020) 135 (5): 371–380.

https://doi.org/10.1182/blood.2019002697

Published: 2020

Includes: Supplemental data

Journal Articles

How I treat acute myeloid leukemia in the era of new drugs

Courtney D. DiNardo, Andrew H. Wei

Blood (2020) 135 (2): 85–96.

https://doi.org/10.1182/blood.2019001239

Published: 2020

Includes: Supplemental data

Journal Articles

Terminal deoxynucleotidyl transferase promotes acute myeloid leukemia by priming FLT3 -ITD replication slippage

Julian Borrow, Sara A. Dyer, Susanna Akiki, Michael J. Griffiths

Blood (2019) 134 (25): 2281–2290.

https://doi.org/10.1182/blood.2019001238

Published: 2019

Includes: Supplemental data

Journal Articles

Molecular roulette: nucleophosmin mutations in AML are orchestrated through N-nucleotide addition by TdT

Julian Borrow, Sara A. Dyer, Susanna Akiki, Michael J. Griffiths

Blood (2019) 134 (25): 2291–2303.

https://doi.org/10.1182/blood.2019001240

Published: 2019

Includes: Supplemental data

Journal Articles

Fludarabine, High Dose Cytarabine and Idarubicin-Based Induction Is Highly Effective in Young AML Patients with Concomitant NPM1 and FLT3-ITD Mutation Irrespectively of FLT3-ITD Allelic Burden

Blood (2019) 134 (Supplement_1): 3828.

https://doi.org/10.1182/blood-2019-131303

Published: 2019

Journal Articles

Safety and Efficacy of Midostaurin in Combination with High-Dose Daunorubicin in 7+3 Induction for Acute Myeloid Leukemia with FLT3 Mutation

Yehuda E. Deutsch, MD, Robert Wilkinson, PharmD, Amanda Brahim, PharmD, Stephanie Boisclair, MD, Jose Sandoval-Sus, MD, Annie Kuehnel, APRN, Terrence J Bradley, MD, Chetasi Talati, MD, Ellen Madarang, PharmD, Jillian Lykon, PharmD, Justin M. Watts, MD, David A Sallman, MD, Kendra L. Sweet, MD, Jeffrey E. Lancet, MD, Hugo F. Fernandez, MD

Blood (2019) 134 (Supplement_1): 3896.

https://doi.org/10.1182/blood-2019-129331

Published: 2019

Journal Articles

First in Human Study of SEL24/MEN1703, First in Class, Orally Available Dual PIM/FLT3 Kinase Inhibitor, in Patients with Acute Myeloid Leukemia

Scott R. Solomon, MD, Aziz Nazha, MD, Stephen A. Strickland, MD, Roland B. Walter, MD PhD MS, Ilaria Valimberti, Alessia Tagliavini, Paolo Mazzei, Caterina Fiesoli, Simona Scartoni, Daniela Bellarosa, Monica Binaschi, PhD, Pawel Chrom, MD PhD, Simone Baldini, MD, Krzysztof Brzózka, PhD, Angela Capriati, Andrea Pellacani, PhD MD, Farhad Ravandi, MD

Blood (2019) 134 (Supplement_1): 3920.

https://doi.org/10.1182/blood-2019-125878

Published: 2019

Journal Articles

Inhibiting Mitochondria Function By Bcl-2 Inhibitor Venetoclax and Complex I Inhibitor Iacs-010759 Eliminate Leukemia Cells in Pre-Clinical AML Models

Qi Zhang, PhD, Alessia Lodi, PhD, Shannon Renee Sweeney, PhD, Lina Han, PhD, Tianyu Cai, PhD, Vinitha Mary Kuruvilla, MSc, Antonio Cavazos, Helen Ma, MS, Yoko Tabe, MD PhD, Joseph R Marszalek, PhD, Stefano Tiziani, PhD, Marina Y Konopleva, MD PhD

Blood (2019) 134 (Supplement_1): 3927.

https://doi.org/10.1182/blood-2019-124494

Published: 2019

Journal Articles

Overcoming Adaptive Therapy Resistance in AML By Targeting Immune Response Pathways

Blood (2019) 134 (Supplement_1): 3934.

https://doi.org/10.1182/blood-2019-124178

Published: 2019

Journal Articles

Dactinomycin in Acute Myeloid Leukemia with NPM1 Mutations

Guillaume Beziat, Suzanne Tavitian, MD, Sarah Bertoli, MD PhD, Francoise Huguet, MD, Laetitia Largeaud, Francois Vergez, DVM, PhD, Jean-Baptiste Rieu, PharmD, Pierre Bories, MD, Eric Delabesse, MD PhD, Christian Recher, MD PhD

Blood (2019) 134 (Supplement_1): 3900.

https://doi.org/10.1182/blood-2019-125782

Published: 2019

Journal Articles

A Phase 1/2 Study of Quizartinib (Q) in Combination with Re-Induction Chemotherapy and As Single-Agent Continuation Therapy in Pediatric and Young Adult Patients with Relapsed/Refractory (R/R) FLT3 -ITD Acute Myeloid Leukemia (AML)

C. Michel Zwaan, MD PhD, Edward Anders Kolb, MD, Derek E. Mires, PharmD, Michele Vigliotti, PharmD, Jingdong Xie, PhD, Pamela Downs, BS, Arthur P DeCillis, MD MS, Cara A Rabik, MD PhD, Todd M Cooper, DO

Blood (2019) 134 (Supplement_1): 3937.

https://doi.org/10.1182/blood-2019-121736

Published: 2019

Journal Articles

Modified Conut Score Can Predict Prognosis in Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia

Hajime Senjo, MD, Masahiro Onozawa, Daisuke Hidaka, Shota Yokoyama, Satoshi Yamamoto, MD PhD, Yutaka Tsutsumi, Yoshihito Haseyama, Takahiro Nagashima, Akio Mori, Shuichi Ota, Hajime Sakai, Toshimichi Ishihara, Takuto Miyagishima, Yasutaka Kakinoki, Mitsutoshi Kurosawa, Hajime Kobayashi, Hiroshi Iwasaki, Takeshi Kondo, Takanori Teshima, MD

Blood (2019) 134 (Supplement_1): 3854.

https://doi.org/10.1182/blood-2019-122804

Published: 2019

Journal Articles

A Phase I/II Study of NMS-03592088, a FLT3, KIT and CSF1R Inhibitor, in Patients with Relapsed or Refractory AML or CMML

Blood (2019) 134 (Supplement_1): 3855.

https://doi.org/10.1182/blood-2019-121954

Published: 2019

Journal Articles

A Multicenter Nonrandom Clinical Study Using Induction Regimen of FLAG-IDA or Dae in Treatment of 101 Children with Newly Diagnosed CBF-AML in South of China: Clinical Responses and the Midterm Report of Survival

Xiaoqin Feng, Jian Li, MD, Chunfu Li, MD, Mincui Zheng, Honggui Xu, Yingyi He, MD& PhD, Changgang Li, MD, Hong Wen, Xiangling He, Lihua Yang, MD PhD

Blood (2019) 134 (Supplement_1): 3857.

https://doi.org/10.1182/blood-2019-126863

Published: 2019

Journal Articles

Phase II Study of Midostaurin + Chemotherapy in Pediatric Patients with Untreated, Newly Diagnosed, FLT3 -Mutated Acute Myeloid Leukemia (AML)

Dirk Reinhardt, MD, Christian Michel Zwaan, Albert Hoenekopp, Julie Niolat, Sophie Ifrah, Florence Noel-Baron, Franco Locatelli, MD

Blood (2019) 134 (Supplement_1): 3835.

https://doi.org/10.1182/blood-2019-128043

Published: 2019

Journal Articles

Combination of CYC065, a Second Generation CDK2/9 Inhibitor, with Venetoclax or Standard Chemotherapies - a Novel Therapeutic Approach for Acute Myeloid Leukaemia (AML)

Wittawat Chantkran, MD MSc, Daniella Zheleva, PhD, Sheelagh Frame, PhD, Ya-Ching Hsieh, PhD, Mhairi Copland, PhD MBBChir, FRCP, FRCPath

Blood (2019) 134 (Supplement_1): 3938.

https://doi.org/10.1182/blood-2019-124072

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Clonal evolution of acute myeloid leukemia with FLT3 -ITD mutation under treatment with midostaurin

Acute myeloid leukemia with NPM1 and FLT3 ITD mimicking acute promyelocytic leukemia

FLT3 inhibition upregulates HDAC8 via FOXO to inactivate p53 and promote maintenance of FLT3-ITD + acute myeloid leukemia

Molecular MRD status and outcome after transplantation in NPM1 -mutated AML

Impact of NPM1 / FLT3 -ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia

How I treat acute myeloid leukemia in the era of new drugs

Terminal deoxynucleotidyl transferase promotes acute myeloid leukemia by priming FLT3 -ITD replication slippage

Molecular roulette: nucleophosmin mutations in AML are orchestrated through N-nucleotide addition by TdT

Fludarabine, High Dose Cytarabine and Idarubicin-Based Induction Is Highly Effective in Young AML Patients with Concomitant NPM1 and FLT3-ITD Mutation Irrespectively of FLT3-ITD Allelic Burden

Safety and Efficacy of Midostaurin in Combination with High-Dose Daunorubicin in 7+3 Induction for Acute Myeloid Leukemia with FLT3 Mutation

First in Human Study of SEL24/MEN1703, First in Class, Orally Available Dual PIM/FLT3 Kinase Inhibitor, in Patients with Acute Myeloid Leukemia

Inhibiting Mitochondria Function By Bcl-2 Inhibitor Venetoclax and Complex I Inhibitor Iacs-010759 Eliminate Leukemia Cells in Pre-Clinical AML Models

Overcoming Adaptive Therapy Resistance in AML By Targeting Immune Response Pathways

Dactinomycin in Acute Myeloid Leukemia with NPM1 Mutations

A Phase 1/2 Study of Quizartinib (Q) in Combination with Re-Induction Chemotherapy and As Single-Agent Continuation Therapy in Pediatric and Young Adult Patients with Relapsed/Refractory (R/R) FLT3 -ITD Acute Myeloid Leukemia (AML)

Modified Conut Score Can Predict Prognosis in Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia

A Phase I/II Study of NMS-03592088, a FLT3, KIT and CSF1R Inhibitor, in Patients with Relapsed or Refractory AML or CMML

A Multicenter Nonrandom Clinical Study Using Induction Regimen of FLAG-IDA or Dae in Treatment of 101 Children with Newly Diagnosed CBF-AML in South of China: Clinical Responses and the Midterm Report of Survival

Phase II Study of Midostaurin + Chemotherapy in Pediatric Patients with Untreated, Newly Diagnosed, FLT3 -Mutated Acute Myeloid Leukemia (AML)

Combination of CYC065, a Second Generation CDK2/9 Inhibitor, with Venetoclax or Standard Chemotherapies - a Novel Therapeutic Approach for Acute Myeloid Leukaemia (AML)

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only